- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Lencioni on the Results of the EMERALD-1 Trial in Unresectable HCC
January 19th 2024, 11:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.
Subgroup Analysis Reveals Higher Incidence of Serious TEAEs With Regorafenib in Patients With uHCC and CP-B Liver Function
January 19th 2024, 10:12pm
Gastrointestinal Cancers Symposium (ASCO GI)
Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.
Fostrox/Lenvatinib Combination Displays Efficacy, Tolerability in Pretreated HCC
January 19th 2024, 9:55pm
Gastrointestinal Cancers Symposium (ASCO GI)
Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.
Frontline Pembrolizumab Plus Lenvatinib Maintains Efficacy, Shows Promising DOR in Advanced HCC
January 19th 2024, 8:52pm
Gastrointestinal Cancers Symposium (ASCO GI)
Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.
Neoadjuvant Camrelizumab/Chemo Combo Shows Clinical Activity in Locally Advanced ESCC
January 19th 2024, 7:23pm
Gastrointestinal Cancers Symposium (ASCO GI)
Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma.
Neoadjuvant Durvalumab Plus Chemo Boosts pCR Vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region
January 19th 2024, 6:20pm
Gastrointestinal Cancers Symposium (ASCO GI)
Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.
Tiragolumab Plus Atezolizumab and Chemotherapy Offers Survival Benefit Over Chemotherapy Alone in ESCC
January 19th 2024, 5:54pm
Gastrointestinal Cancers Symposium (ASCO GI)
Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.
Dr Shah on the 5-Year Survival Outcomes From the KEYNOTE-590 Study in Esophageal Cancer
January 19th 2024, 1:42am
Gastrointestinal Cancers Symposium (ASCO GI)
Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.
ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers
January 18th 2024, 10:10pm
Gastrointestinal Cancers Symposium (ASCO GI)
ASKB589 demonstrated anti-tumor activity in combination with capecitabine and oxaliplatin plus sintilimab in gastric or gastroesophageal junction cancers.
First-Line Nivolumab Plus Chemotherapy Shows Real-World Efficacy in Gastric/GEJ/Esophageal Cancers
January 18th 2024, 5:51pm
Gastrointestinal Cancers Symposium (ASCO GI)
Real-world findings demonstrated a favorable survival benefit with nivolumab plus chemotherapy in advanced gastroesophageal adenocarcinoma.
Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC
January 10th 2024, 4:48pm
Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.
Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors
January 9th 2024, 8:30pm
Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.
Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC
January 5th 2024, 9:35pm
Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.
Lenvatinib/Pembrolizumab/Chemo Induces Inferior OS vs Pembrolizumab/Chemo in Previously Untreated NSCLC
January 5th 2024, 9:00pm
Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.
Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma
January 5th 2024, 8:00pm
Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.
Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma
January 5th 2024, 4:00pm
Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.
Lenvatinib Plus Pembrolizumab Fails to Improve OS and PFS Over Docetaxel in Stage IV NSCLC
January 4th 2024, 9:53pm
Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC
January 4th 2024, 8:20pm
The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.
Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC
January 4th 2024, 8:00pm
Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.
POSEIDON Update Confirms OS Benefit of Tremelimumab/Durvalumab Plus Chemo in mNSCLC
January 3rd 2024, 8:33pm
A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.